Stephanie Staelens

USPTO Granted Patents = 22 (Patent Applications = 20)

CIPO Patents = 3 (Patent Applications = 10)

EPO Patents = 11 (Patent Applications = 28)

Average Co-Inventor Count = 5.3

ph-index = 5

Forward Citations = 77(Granted Patents)

Location History:

Wevelgem, BE (2012 - 2024)
Zwijnaarde, BE (2020 - 2024)

Company Filing History:

Boehringer Ingelheim International Gmbh

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12285493 - Polypeptides antagonizing Wnt signaling in tumor cells (2025-04-29),

2. 12006352 - Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains (2024-06-11),

3. 11952418 - Biparatopic polypeptides antagonizing Wnt signaling in tumor cells (2024-04-09),

4. 11897944 - Immunoglobulin single variable domain (ISVD) capable of binding to serum albumin (2024-02-13),

5. 11644471 - Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains (2023-05-09),

6. 11466089 - Chemokine receptor binding polypeptides (2022-10-11),

7. 11414481 - Serum albumin binders (2022-08-16),

8. 11414480 - Serum albumin binding immunoglobulin single variable domains (2022-08-16),

9. 11192938 - Serum albumin binding proteins containing immunoglobulin single variable domains (2021-12-07),

10. 11192937 - Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains (2021-12-07),

11. 11033636 - Polypeptides antagonizing Wnt signaling in tumor cells (2021-06-15),

12. 11028151 - Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections (2021-06-08),

13. 10858418 - Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains (2020-12-08),

14. 10822425 - Single variable domain antibodies against OX40L, constructs and therapeutic use (2020-11-03),

15. 10597449 - Biparatopic polypeptides antagonizing Wnt signaling in tumor cells (2020-03-24),

Title: The Innovations of Stephanie Staelens

Introduction

Stephanie Staelens, based in Wevelgem, Belgium, is a notable inventor recognized for his significant contributions to the field of biotechnology. With a remarkable portfolio of 21 patents, his innovative solutions have advanced the understanding and treatment of various diseases, particularly in immunology and oncology.

Latest Patents

Among Stephanie's latest patents is a groundbreaking invention titled "Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains." This invention describes assays that can predict whether a given immunoglobulin single variable domain (ISV) will experience protein interference in various assays, including ADA immunoassays. The predictive capabilities of these assays can help guide the selection and modification of ISVs to minimize interference, enhancing the accuracy and reliability of immunological assays.

Another notable patent is for "Biparatopic polypeptides antagonizing Wnt signaling in tumor cells," which introduces novel biparatopic polypeptides that can inhibit Wnt signaling pathways critical for tumor cell growth. This invention encompasses specific polypeptide sequences, methods for their production, and their therapeutic applications in treating diseases like cancer.

Career Highlights

Stephanie Staelens has had a distinguished career with notable positions in leading companies in the pharmaceutical and biotechnology sectors, including Ablynx N.V. and Boehringer Ingelheim International GmbH. His expertise in drug development and assay technology has positioned him as a leader in creating innovative solutions for complex biological challenges.

Collaborations

Throughout his career, Stephanie has collaborated with talented individuals such as Marie-Ange Buyse and Soren Steffensen. These collaborations have fostered a rich environment for innovation, enabling the development of new technologies and patentable inventions that address critical healthcare needs.

Conclusion

Stephanie Staelens's impressive portfolio of patents and his impactful career in biotechnology underscore his role as a leading inventor. His work not only contributes to scientific advancements but also holds the potential for significant benefits in the treatment of serious health conditions. As he continues to innovate, we can anticipate further breakthroughs from this accomplished inventor.

This text is generated by artificial intelligence and may not be accurate.